<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04789850</url>
  </required_header>
  <id_info>
    <org_study_id>P180613</org_study_id>
    <secondary_id>2019-003430-16</secondary_id>
    <nct_id>NCT04789850</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Itacitinib in Adults With Systemic Sclerosis</brief_title>
  <acronym>SCLERITA</acronym>
  <official_title>Safety and Efficacy of Itacitinib in Adults With Systemic Sclerosis: a Phase II, Randomized, Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether itacitinib is safe and effective in the&#xD;
      treatment of systemic sclerosis in adults.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Systemic sclerosis (SSc) is a rare systemic autoimmune connective tissue-disease&#xD;
      characterized by fibrosis, inflammation, and vasculopathy. SSc is responsible for skin&#xD;
      fibrosis that can either be limited or diffuse. The latter phenotype of the disease is&#xD;
      commonly associated with visceral involvement and therefore similar to graft versus host&#xD;
      disease (GvHD) reaction. It can be life threatening in case of pulmonary or cardiovascular&#xD;
      involvement. Nonetheless SSc remains a severe disease responsible for important disability&#xD;
      and a poor quality of life.&#xD;
&#xD;
      There is a growing body of evidence that supports the implication of the JAK-STAT tyrosine&#xD;
      kinases pathway in the activation of fibroblasts of patients with SSc. A genetic polymorphism&#xD;
      of STAT4 was found to be associated with the diffuse form of the disease and inhibition of&#xD;
      STAT4 gene is associated with a decrease in TGF-ß and IL-6 cytokines activation, which are&#xD;
      two major cytokines implicated in SSc pathogenesis. Recently, Pedroza et al. confirmed the&#xD;
      implication of STAT3 in skin fibrosis mechanisms. Indeed, the authors showed an enhanced&#xD;
      activation of STAT3 and demonstrated in vivo that the inhibition of STAT3 phosphorylation&#xD;
      prevented skin fibrosis in a murine model of SSc. These data were confirmed by a work of&#xD;
      Zhang et al. who showed that the inhibition of JAK1 was also needed to prevent skin and lung&#xD;
      fibrosis. Altogether these works confirmed the implication of the JAK pathway in fibrosis&#xD;
      mechanism.&#xD;
&#xD;
      Itacitinib is a Janus kinase inhibitor that specifically targets JAK1 and decreases STAT3&#xD;
      phosphorylation. Itacitinib was shown to efficiently treat patients with myelofibrosis,&#xD;
      rheumatoid arthritis, and chronic plaque psoriasis. Very interestingly, itacitinib efficacy&#xD;
      has also been reported in patients with acute GvHD. Altogether these data and studies&#xD;
      reinforced the investigator's working hypothesis.&#xD;
&#xD;
      The efficacy and safety of this proposal must be tested.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 2021</start_date>
  <completion_date type="Anticipated">June 2024</completion_date>
  <primary_completion_date type="Anticipated">June 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in modified Rodnan skin score (mRSS) at 360 days</measure>
    <time_frame>360 days</time_frame>
    <description>performed by the same investigator at day 0 and day 360 and the change in mRSS will be calculated following the formula: ΔmRSS= mRSSd360 - mRSSd0.&#xD;
To measure mRSS, skin thickness of the patient is rated by palpation at each of 17 anatomic sites using a scale of 0-3 (0 = normal skin; 1= mild thickness; 2= moderate thickness; 3=severe thickness with an inability to pinch the skin into a fold). The scores at each site are summed with a minimum of 0 and a maximum of 51 (17 sites)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of death</measure>
    <time_frame>at 180 and 360 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Adverse Events</measure>
    <time_frame>at 180 and 360 days</time_frame>
    <description>according to the Common Terminology Criteria for Adverse Events (CTCAE) toxicity grading scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Severe Adverse Events</measure>
    <time_frame>at 180 and 360 days</time_frame>
    <description>according to the Common Terminology Criteria for Adverse Events (CTCAE) toxicity grading scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in modified Rodnan skin score at 90, 180, 270 days</measure>
    <time_frame>at 90, 180 and 270 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients who improved mRSS at 90, 180, 270 and 360 days</measure>
    <time_frame>At 90, 180, 270 and 360 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with an active disease according to the European scleroderma trials and research group (EUSTAR)SSc activity score at 90, 180, 270 and 360 days</measure>
    <time_frame>At 90, 180, 270 and 360 days</time_frame>
    <description>EUSTAR SSc activity index score from 0 to 10 - a cut-off ≥ 2.5 identifies patients with active disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the Combined Response Index in Diffuse Systemic Sclerosis (CRISS) score</measure>
    <time_frame>At 180 and 360 days</time_frame>
    <description>composite response index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SSc disease activity</measure>
    <time_frame>At 90, 180, 270 and 360 days</time_frame>
    <description>Physicians visual analogue scale range from 0 (min) to 10 (max) - 0=no activity, 10=maximum activity&#xD;
Patients visual analogue scale range from 0 (min) to 10 (max) - 0=no activity, 10=maximum activity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Short Form-36 (SF-36) health questionnaire</measure>
    <time_frame>At 0, 15, 90, 180, 270 and 360 days</time_frame>
    <description>self-administered questionnaire of 36 items assessing the following 8 domains : physical functioning, bodily pain, role limitations attributable to physical health problems, general health perceptions, mental health, role limitations to emotional problems, vitality and social functioning (scale from 0 to 100)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EurolQol-5Domain (EQ-5D) health questionnaire</measure>
    <time_frame>At 0, 15, 90, 180, 270 and 360 days</time_frame>
    <description>self reported measure of quality of life - (scale from 0 to 100)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health Assessment Questionnaire Disability Index (HAQ-DI) scale</measure>
    <time_frame>At 0, 15, 90, 180, 270 and 360 days</time_frame>
    <description>self administered 20 questions- score range from 0 (no disability) to 3 (severe disability)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">74</enrollment>
  <condition>Systemic Sclerosis</condition>
  <arm_group>
    <arm_group_label>Itacitinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>200mg of oral Itacitinib everyday for 360 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Oral placebo everyday for 360 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Itacitinib</intervention_name>
    <description>200 mg oral for 360 days</description>
    <arm_group_label>Itacitinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>200 mg oral for 360 days</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult patient (≥18 years old)&#xD;
&#xD;
          -  Patient with a diagnosis of diffuse SSc, as defined by the American College of&#xD;
             Rheumatology / EULAR 2013 criteria,&#xD;
&#xD;
          -  Patient with a SSc disease duration of less than 36 months (defined as time from first&#xD;
             non-Raynaud phenomenon manifestation) or with an active SSc disease, as defined by&#xD;
             EUSTAR disease activity score,&#xD;
&#xD;
          -  Patient with a modified Rodnan skin score (mRSS) ≥ 10 and ≤ 35 units at screening,&#xD;
&#xD;
          -  Negative pregnancy test for woman of childbearing potential, woman of childbearing&#xD;
             potential should have reliable contraception for the 12 months' duration of the study,&#xD;
&#xD;
          -  Patient able to give written informed consent prior to participation in the study,&#xD;
&#xD;
          -  Affiliation to a social security scheme (profit or being entitled).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous treatment with itacitinib or a Janus kinase (JAK) inhibitor,&#xD;
&#xD;
          -  Contra-indications to itacitinib or Janus kinase inhibitor,&#xD;
&#xD;
          -  Failure to sign the informed consent or unable to consent&#xD;
&#xD;
          -  Patient participating in another investigational therapeutic study,&#xD;
&#xD;
          -  Current, or history of recurrent infections, including HBV, HCV, HIV,&#xD;
&#xD;
          -  Patient with other uncontrolled diseases, including drug or alcohol abuse, severe&#xD;
             psychiatric diseases, that could interfere with participation in the trial according&#xD;
             to the protocol,&#xD;
&#xD;
          -  Patient suspected not to be observant to the proposed treatments,&#xD;
&#xD;
          -  Patient who have white blood cell count ≤ 4,000/mm3,&#xD;
&#xD;
          -  Patient who have platelet count ≤ 100,000/mm3,&#xD;
&#xD;
          -  Patients who have ALT or AST level greater that 3 times the upper limit of normal,&#xD;
&#xD;
          -  Patient who have triglyceride level greater than 5g/L&#xD;
&#xD;
          -  Pregnant or breastfeeding woman,&#xD;
&#xD;
          -  Protected adults (including individual under guardianship by court order),&#xD;
&#xD;
          -  Patient receiving or having received mycophenolate mofetil or methotrexate within the&#xD;
             last month (possible inclusion beyond one month),&#xD;
&#xD;
          -  Patient receiving or having received cyclophosphamide or rituximab within the last&#xD;
             three months (possible inclusion beyond 3 months),&#xD;
&#xD;
          -  Patient receiving or having received a biotherapy (anti-TNF, abatacept or tocilizumab)&#xD;
             in the last 3 months (possible inclusion beyond 3 months)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Luc Mouthon, MD-PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Benjamin Chaigne, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Benjamin Chaigne, MD</last_name>
    <phone>+33 1 58 41 41 17</phone>
    <email>benjamin.chaigne@aphp.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Audrey Béclin-Clabaux</last_name>
    <phone>+33 1 58 41 33 82</phone>
    <email>audrey.clabaux@aphp.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CH Amiens</name>
      <address>
        <city>Amiens</city>
        <zip>80000</zip>
        <country>France</country>
      </address>
    </facility>
    <investigator>
      <last_name>Catherine LOK, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Angers</name>
      <address>
        <city>Angers</city>
        <zip>49100</zip>
        <country>France</country>
      </address>
    </facility>
    <investigator>
      <last_name>Christian LAVIGNE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Annecy</name>
      <address>
        <city>Annecy</city>
        <zip>74370</zip>
        <country>France</country>
      </address>
    </facility>
    <investigator>
      <last_name>Alice BEREZNE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Avicenne Hospital</name>
      <address>
        <city>Bobigny</city>
        <zip>93022</zip>
        <country>France</country>
      </address>
    </facility>
    <investigator>
      <last_name>Yurdagul UZUNHAN, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Bordeaux</name>
      <address>
        <city>Bordeaux</city>
        <zip>33000</zip>
        <country>France</country>
      </address>
    </facility>
    <investigator>
      <last_name>Marie-Elise TRUCHETET, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ambroise Paré hospital</name>
      <address>
        <city>Boulogne-Billancourt</city>
        <zip>92100</zip>
        <country>France</country>
      </address>
    </facility>
    <investigator>
      <last_name>Laetitia COUTTE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Caen</name>
      <address>
        <city>Caen</city>
        <zip>14000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Gabriel Montpied</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63000</zip>
        <country>France</country>
      </address>
    </facility>
    <investigator>
      <last_name>Marc ANDRE, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Henry Mondor hospital</name>
      <address>
        <city>Créteil</city>
        <zip>94000</zip>
        <country>France</country>
      </address>
    </facility>
    <investigator>
      <last_name>Nicolas LIMAL, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Dijon</name>
      <address>
        <city>Dijon</city>
        <zip>21000</zip>
        <country>France</country>
      </address>
    </facility>
    <investigator>
      <last_name>Sabine BERTHIER, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Grenoble</name>
      <address>
        <city>Grenoble</city>
        <zip>38700</zip>
        <country>France</country>
      </address>
    </facility>
    <investigator>
      <last_name>Bernard IMBERT, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Grenoble</name>
      <address>
        <city>Grenoble</city>
        <zip>38700</zip>
        <country>France</country>
      </address>
    </facility>
    <investigator>
      <last_name>Laurence BOUILLET, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Lille</name>
      <address>
        <city>Lille</city>
        <zip>59000</zip>
        <country>France</country>
      </address>
    </facility>
    <investigator>
      <last_name>Eric HACHULLA, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Limoges</name>
      <address>
        <city>Limoges</city>
        <zip>87000</zip>
        <country>France</country>
      </address>
    </facility>
    <investigator>
      <last_name>Anne-Laure FAUCHAIS, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Lyon sud</name>
      <address>
        <city>Lyon</city>
        <zip>69310</zip>
        <country>France</country>
      </address>
    </facility>
    <investigator>
      <last_name>Jean-christophe LEGA, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Nord</name>
      <address>
        <city>Marseille</city>
        <zip>13015</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>La Timone Hospital</name>
      <address>
        <city>Marseille</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
    <investigator>
      <last_name>Marie-Aleth RICHARD, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>La Timone Hospital</name>
      <address>
        <city>Marseille</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
    <investigator>
      <last_name>Jean-Robert HARLE, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Montpellier - rhumatology</name>
      <address>
        <city>Montpellier</city>
        <zip>34090</zip>
        <country>France</country>
      </address>
    </facility>
    <investigator>
      <last_name>Jacques MOREL, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Montpellier - St Eloi Hospital</name>
      <address>
        <city>Montpellier</city>
        <zip>34090</zip>
        <country>France</country>
      </address>
    </facility>
    <investigator>
      <last_name>Philippe GUILPAIN, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Nancy</name>
      <address>
        <city>Nancy</city>
        <zip>54035</zip>
        <country>France</country>
      </address>
    </facility>
    <investigator>
      <last_name>Denis WAHL, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Nantes</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <investigator>
      <last_name>Christian AGARD, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Pasteur - CHU Nice</name>
      <address>
        <city>Nice</city>
        <zip>06000</zip>
        <country>France</country>
      </address>
    </facility>
    <investigator>
      <last_name>Viviane QUEYREL, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint Antoine Hospital</name>
      <address>
        <city>Paris</city>
        <zip>75012</zip>
        <country>France</country>
      </address>
    </facility>
    <investigator>
      <last_name>Arsène MEKINIAN, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cochin Hospital</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Benjamin Chaigne, MD</last_name>
      <phone>+33 1 58 41 41 17</phone>
      <email>benjamin.chaigne@aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Yannick ALLANORE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Croix St Simon</name>
      <address>
        <city>Paris</city>
        <zip>75020</zip>
        <country>France</country>
      </address>
    </facility>
    <investigator>
      <last_name>Jonathan LONDON, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Poitiers</name>
      <address>
        <city>Poitiers</city>
        <zip>86021</zip>
        <country>France</country>
      </address>
    </facility>
    <investigator>
      <last_name>Mickael MARTIN, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Robert Debré Hospital</name>
      <address>
        <city>Reims</city>
        <zip>51100</zip>
        <country>France</country>
      </address>
    </facility>
    <investigator>
      <last_name>Amélie SERVETTAZ, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Sud</name>
      <address>
        <city>Rennes</city>
        <zip>35200</zip>
        <country>France</country>
      </address>
    </facility>
    <investigator>
      <last_name>Patrick JEGO, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Rouen</name>
      <address>
        <city>Rouen</city>
        <zip>76000</zip>
        <country>France</country>
      </address>
    </facility>
    <investigator>
      <last_name>Ygal BENHAMOU, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nouvel Hospital Civil</name>
      <address>
        <city>Strasbourg</city>
        <zip>67000</zip>
        <country>France</country>
      </address>
    </facility>
    <investigator>
      <last_name>Thierry MARTIN, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rangueil Hospital</name>
      <address>
        <city>Toulouse</city>
        <zip>31400</zip>
        <country>France</country>
      </address>
    </facility>
    <investigator>
      <last_name>Grégory PUGNET, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Tours</name>
      <address>
        <city>Tours</city>
        <zip>37000</zip>
        <country>France</country>
      </address>
    </facility>
    <investigator>
      <last_name>Elisabeth DIOT, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH Valenciennes</name>
      <address>
        <city>Valenciennes</city>
        <zip>59300</zip>
        <country>France</country>
      </address>
    </facility>
    <investigator>
      <last_name>Thomas QUEMENEUR, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Almeida C, Almeida I, Vasconcelos C. Quality of life in systemic sclerosis. Autoimmun Rev. 2015 Dec;14(12):1087-96. doi: 10.1016/j.autrev.2015.07.012. Epub 2015 Jul 23. Review.</citation>
    <PMID>26212726</PMID>
  </reference>
  <reference>
    <citation>Mouthon L. SSc in 2011: From mechanisms to medicines. Nat Rev Rheumatol. 2012 Jan 10;8(2):72-4. doi: 10.1038/nrrheum.2011.203.</citation>
    <PMID>22231235</PMID>
  </reference>
  <reference>
    <citation>Distler JH, Feghali-Bostwick C, Soare A, Asano Y, Distler O, Abraham DJ. Review: Frontiers of Antifibrotic Therapy in Systemic Sclerosis. Arthritis Rheumatol. 2017 Feb;69(2):257-267. doi: 10.1002/art.39865. Review.</citation>
    <PMID>27636741</PMID>
  </reference>
  <reference>
    <citation>Wang Y, Fan PS, Kahaleh B. Association between enhanced type I collagen expression and epigenetic repression of the FLI1 gene in scleroderma fibroblasts. Arthritis Rheum. 2006 Jul;54(7):2271-9.</citation>
    <PMID>16802366</PMID>
  </reference>
  <reference>
    <citation>Landi C, Bargagli E, Bianchi L, Gagliardi A, Carleo A, Bennett D, Perari MG, Armini A, Prasse A, Rottoli P, Bini L. Towards a functional proteomics approach to the comprehension of idiopathic pulmonary fibrosis, sarcoidosis, systemic sclerosis and pulmonary Langerhans cell histiocytosis. J Proteomics. 2013 May 27;83:60-75. doi: 10.1016/j.jprot.2013.03.006. Epub 2013 Mar 23.</citation>
    <PMID>23528693</PMID>
  </reference>
  <reference>
    <citation>Kubo M, Ihn H, Yamane K, Tamaki K. Up-regulated expression of transforming growth factor beta receptors in dermal fibroblasts in skin sections from patients with localized scleroderma. Arthritis Rheum. 2001 Mar;44(3):731-4.</citation>
    <PMID>11263790</PMID>
  </reference>
  <reference>
    <citation>Zhang Y, Liang R, Chen CW, Mallano T, Dees C, Distler A, Reich A, Bergmann C, Ramming A, Gelse K, Mielenz D, Distler O, Schett G, Distler JHW. JAK1-dependent transphosphorylation of JAK2 limits the antifibrotic effects of selective JAK2 inhibitors on long-term treatment. Ann Rheum Dis. 2017 Aug;76(8):1467-1475. doi: 10.1136/annrheumdis-2016-210911. Epub 2017 May 6.</citation>
    <PMID>28478401</PMID>
  </reference>
  <reference>
    <citation>Migita K, Izumi Y, Torigoshi T, Satomura K, Izumi M, Nishino Y, Jiuchi Y, Nakamura M, Kozuru H, Nonaka F, Eguchi K, Kawakami A, Motokawa S. Inhibition of Janus kinase/signal transducer and activator of transcription (JAK/STAT) signalling pathway in rheumatoid synovial fibroblasts using small molecule compounds. Clin Exp Immunol. 2013 Dec;174(3):356-63. doi: 10.1111/cei.12190.</citation>
    <PMID>23968543</PMID>
  </reference>
  <reference>
    <citation>Xu Y, Wang W, Tian Y, Liu J, Yang R. Polymorphisms in STAT4 and IRF5 increase the risk of systemic sclerosis: a meta-analysis. Int J Dermatol. 2016 Apr;55(4):408-16. doi: 10.1111/ijd.12839. Epub 2015 Dec 29. Review.</citation>
    <PMID>26712637</PMID>
  </reference>
  <reference>
    <citation>Avouac J, Fürnrohr BG, Tomcik M, Palumbo K, Zerr P, Horn A, Dees C, Akhmetshina A, Beyer C, Distler O, Schett G, Allanore Y, Distler JH. Inactivation of the transcription factor STAT-4 prevents inflammation-driven fibrosis in animal models of systemic sclerosis. Arthritis Rheum. 2011 Mar;63(3):800-9. doi: 10.1002/art.30171.</citation>
    <PMID>21360510</PMID>
  </reference>
  <reference>
    <citation>Kremer JM, Bloom BJ, Breedveld FC, Coombs JH, Fletcher MP, Gruben D, Krishnaswami S, Burgos-Vargas R, Wilkinson B, Zerbini CA, Zwillich SH. The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo. Arthritis Rheum. 2009 Jul;60(7):1895-905. doi: 10.1002/art.24567. Erratum in: Arthritis Rheum. 2012 May;64(5):1487.</citation>
    <PMID>19565475</PMID>
  </reference>
  <reference>
    <citation>Fridman JS, Scherle PA, Collins R, Burn T, Neilan CL, Hertel D, Contel N, Haley P, Thomas B, Shi J, Collier P, Rodgers JD, Shepard S, Metcalf B, Hollis G, Newton RC, Yeleswaram S, Friedman SM, Vaddi K. Preclinical evaluation of local JAK1 and JAK2 inhibition in cutaneous inflammation. J Invest Dermatol. 2011 Sep;131(9):1838-44. doi: 10.1038/jid.2011.140. Epub 2011 Jun 16.</citation>
    <PMID>21677670</PMID>
  </reference>
  <reference>
    <citation>Deverapalli SC, Rosmarin D. The use of JAK inhibitors in the treatment of progressive systemic sclerosis. J Eur Acad Dermatol Venereol. 2018 Aug;32(8):e328. doi: 10.1111/jdv.14876. Epub 2018 Mar 6.</citation>
    <PMID>29444362</PMID>
  </reference>
  <reference>
    <citation>Gordon JK, Martyanov V, Franks JM, Bernstein EJ, Szymonifka J, Magro C, Wildman HF, Wood TA, Whitfield ML, Spiera RF. Belimumab for the Treatment of Early Diffuse Systemic Sclerosis: Results of a Randomized, Double-Blind, Placebo-Controlled, Pilot Trial. Arthritis Rheumatol. 2018 Feb;70(2):308-316. doi: 10.1002/art.40358. Epub 2017 Dec 29.</citation>
    <PMID>29073351</PMID>
  </reference>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>February 10, 2021</study_first_submitted>
  <study_first_submitted_qc>March 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 10, 2021</study_first_posted>
  <last_update_submitted>March 8, 2021</last_update_submitted>
  <last_update_submitted_qc>March 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Systemic sclerosis</keyword>
  <keyword>Itacitinib</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Scleroderma, Systemic</mesh_term>
    <mesh_term>Scleroderma, Diffuse</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

